HROW Harrow Health Inc.

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after the Nasdaq market close. The Company will also post its fourth quarter Letter to Shareholders to the “Investors” section of its website, . Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern time to discuss the results and provide a business update.

Conference Call Details: 
Date:Monday, March 8, 2021
Time:4:45 p.m. Eastern time
Participant Dial-in:(888) 506-0062 (U.S.)

(973) 528-0011 (International)
Replay Dial-in (Passcode 39840):

(telephonic replay through April 8, 2021)
(877) 481-4010 (U.S.)

(919) 882-2331 (International)
Webcast:

(online replay through June 8, 2021)

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns , the nation’s leading ophthalmology outsourcing and pharmaceutical compounding business, which was founded in 2014. Harrow Health also holds large equity positions in , and , all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, .

Contact:

Jamie Webb, Director of Communications and Investor Relations



615-733-4737



 



EN
25/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due...

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has commenced a private offering (the “Offering”) of $250.0 million aggregate principal amount of senior unsecured notes due 2030 (the “2030 Notes”), subject to market and certain other conditi...

 PRESS RELEASE

Harrow Announces Second-Quarter 2025 Financial Results

Harrow Announces Second-Quarter 2025 Financial Results Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quar...

 PRESS RELEASE

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conferen...

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually. Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discuss...

 PRESS RELEASE

Harrow To Report Second Quarter 2025 Financial Results After Market C...

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 12, 2025 NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, . Har...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch